Foghorn Therapeutics (FHTX) Earnings Date & Reports

Key Takeaways

• Foghorn Therapeutics (FHTX) is expected to report its third-quarter 2026 results in early November 2026, marking the company's next quarterly update.
• Wall Street consensus estimates call for a net loss of roughly $0.23 per share on revenue of approximately $6.4 million, according to MarketBeat.
• In the year-ago quarter, the company posted a net loss of $0.25 per share on revenue of $8.15 million, providing a comparison baseline.
• In Q2 2026, FHTX reported a narrower loss of $0.10 per share and revenue of $16.07 million, boosted by a $14.2 million catch-up payment tied to its Eli Lilly collaboration.
• Investors will watch the company's cash runway (about $167.6 million as of June 30, 2026, extending into the first half of 2028) and updates on its oncology pipeline, including the CBPd-171 program.
• For more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these additional pages for deeper context.
• To discover AI-driven trading ideas and strategies, explore Trending AI Robots.

Earnings Context and Why It Matters

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the chromatin regulatory system, the mechanism that controls which genes are turned on or off. Its quarterly updates carry outsized importance because, as a development-stage business, the company generates most of its revenue from collaborations rather than product sales. Investors therefore look beyond top-line figures to assess pipeline momentum, collaboration milestones, and spending discipline. The Q3 2026 report arrives after a volatile stretch in which quarterly revenue swung sharply due to non-recurring collaboration payments, while the CBPd-171 program reportedly faced operational delays. With a cash runway extending into the first half of 2028, the update will help clarify whether Foghorn's programs remain on track and how efficiently management is deploying capital.

Earnings Expectations

Analysts expect Foghorn Therapeutics to report a net loss of approximately $0.23 per share on revenue of about $6.4 million for the third quarter of 2026, based on consensus data from MarketBeat. Estimates vary modestly across research providers, with some consensus figures near a $0.25 per-share loss on revenue closer to $7.2 million. For comparison, the company reported a net loss of $0.25 per share on revenue of $8.15 million in the prior-year quarter. Last quarter, FHTX delivered a net loss of $0.10 per share and revenue of $16.07 million, substantially beating expectations largely because of a $14.2 million catch-up payment recognized under its Eli Lilly collaboration. Given that collaboration-driven revenue can be lumpy and unpredictable, investors will likely focus less on the headline figures and more on pipeline timelines, research and development (R&D) expense trends, and updated cash runway guidance.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters, including industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves like those around Foghorn Therapeutics, the AI Screener can help identify related patterns and opportunities across the biotechnology sector.

Market Reaction and Investor Sentiment

Sentiment heading into Foghorn's Q3 2026 report reflects a mix of cautious optimism and uncertainty. The company's Q2 2026 results triggered a notable stock reaction after a large revenue beat, but much of that upside stemmed from a one-time collaboration adjustment rather than recurring revenue. Investors entering this print are likely weighing several risk factors: the operational delays reported around the CBPd-171 program, the inherent lumpiness of collaboration revenue, and whether R&D spending reductions seen in recent quarters are sustainable without slowing pipeline progress. As a clinical-stage company with a limited revenue base, FHTX's share price can be highly sensitive to even small changes in guidance, pipeline timing, or cash runway commentary. Broader biotech market conditions, including risk appetite for early-stage oncology names, may also influence the immediate market response.

Forward Outlook and Key Factors to Monitor

Following the Q3 2026 release, investors should track several forward-looking signals rather than the headline earnings figures alone. First, cash runway is a central concern for any development-stage biotech. Management's commentary on whether the company's roughly $167.6 million cash position still supports operations into the first half of 2028 will be closely scrutinized, especially if spending plans shift.

Second, pipeline execution matters more than near-term revenue. Updates on the CBPd-171 program, including any revised timelines after reported operational delays, will be a key focus. Investors will also watch for progress across Foghorn's broader oncology portfolio and its ongoing collaboration with Eli Lilly, which has been a meaningful source of revenue and validation.

Third, cost discipline deserves attention. R&D expense trends, which declined in recent quarters, can signal how efficiently the company is advancing its programs. A sustained reduction could extend the runway but raise questions about pipeline pace, while an increase might indicate acceleration into new clinical stages.

Finally, watch for any guidance or milestone announcements that could serve as near-term catalysts, such as data readouts, regulatory updates, or new collaboration activity. Each of these factors can influence how the market interprets the company's path from development-stage biotech toward a more commercially positioned player.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations